ArticleAmerican journal of public health2007
The effect of antidepressant warnings on prescribing trends in Ontario, Canada.
Article in American journal of public health, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Measuring the impact of medicines regulatory interventions - Systematic review and methodological considerations.British journal of clinical pharmacology · 2018Pooled it
- Impact of safety-related regulatory action on clinical practice: a systematic review.Drug safety · 2012Pooled it
- Medication Prescribed Within One Year Preceding Fall-Related Injuries in Ontario Older Adults.Canadian geriatrics journal : CGJ · 2022Article
- Food and Drug Administration Safety Communication on the Use of Transvaginal Mesh in Pelvic Organ Prolapse Repair Surgery: The Impact of Social Determinants of Health.Female pelvic medicine & reconstructive surgery · 2021Observational
- The Impact of US FDA and Health Canada Warnings Related to the Safety of High-dose Simvastatin.Drugs - real world outcomes · 2017Article
- Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2016Article
- Psychopharmacological Prescriptions in Children and Adolescents in Germany.Deutsches Arzteblatt international · 2016Article
- Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study.SAGE open medicine · 2016Article
- Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).Drug safety · 2014Article
- The pharmacoepidemiology of selective serotonin reuptake inhibitors for children and adolescents in Canada from 2005 to 2009: a database analysis.Paediatric drugs · 2013Article
- Health advisories and patterns of patient monitoring among new users of antidepressant medications.Journal of clinical psychopharmacology · 2009Article
- Effectiveness of safety warnings in atypical antipsychotic drugs: an interrupted time-series analysis in Spain.Drug safety · 2009Article
- Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Article
- Health advisories: when good intentions go bad.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesWe studied whether 5 regulatory agency advisories concerning the possible increased risk of suicidal behavior during antidepressant therapy had an effect on antidepressant prescription trends in Ontario.
methodsWe conducted a population-based, time-series analysis of new monthly antidepressant prescriptions dispensed by the Ontario Drug Benefits program in 3 age groups (younger than 20 years, 20-65 years old, and older than 65 years) over a 7-year period (April 1998 to March 2005). The impact of five advisories about the possible risk of suicide during antidepressant therapy was also analyzed.
resultsThe number of new prescriptions for selective serotonin reuptake inhibitors as a group did not change after any antidepressant warning in any age group. However, the rate of new paroxetine prescriptions in patients younger than 20 years declined by 54% immediately after the first warning for paroxetine was issued in the United Kingdom in June 2003. That same warning had no effect on new paroxetine prescriptions in the other age categories.
conclusionThe warning about paroxetine use in depressed patients younger than 18 years that was issued in the United Kingdom led to a significant decrease in new paroxetine prescriptions for young patients in this country. By contrast, warnings in North America did not influence new antidepressant prescription rates in any patient group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.